Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 751-758

  Gao, Mei Hua ^a   Hammond, H Kirk ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus vector; Adrenergic signaling; Animal models; Congestive heart failure; Cyclic AMP; Gene therapy; Nitroprusside

Indexed keywords

ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ADENYLATE CYCLASE 6; CYCLIC AMP; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CARDIOVASCULAR RESPONSE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ADENYLATE CYCLASE; ANIMALS; CYCLIC AMP; GENE THERAPY; HEART FAILURE; HEART VENTRICLES; HUMANS; MICE; RATS;

ADENOVIRIDAE; ANIMALIA; MUS; RATTUS; SUIDAE;

EID: 79953674475     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.02.009     Document Type: Review

References (100)

1. Ostrom R.S., Violin J.D., Coleman S., Insel P.A. Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. Mol Pharmacol 2000, 57:1075-1079.
2. Ostrom R.S., Naugle J.E., Hase M., Gregorian C., Swaney J.S., Insel P.A., Brunton L.L., Meszaros J.G. enhances adenylyl cyclase signaling via Ca2+/calmodulin. Gq-Gs cross-talk redulates collagen production in cardiac fibroblasts. J Biol Chem 2003, 278:24461-24468.
3. Liu X., Ostrom R.S., Insel P.A. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 2004, 286:C1089-C1099.
4. Head B.P., Patel H.H., Roth D.M., Murray F., Swaney J.S., Niesman I.R., Farquhar M.G., Insel P.A. Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem 2006, 281:26391-26399.
5. Swaney J.S., Patel H.H., Yokoyama U., Lai N.C., Spellman M., Insel P.A., Roth D.M. Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 293:H3216-H3220.
6. Beazely M.A., Alan J.K., Watts V.J. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Mol Pharmacol 2005, 67:250-259.
7. Beazely M.A., Watts V.J. Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochem Pharmacol 2005, 70:113-120.
8. Beazely M.A., Watts V.J. Regulatory properties of adenylate cyclases type 5 and 6: a progress report. Eur J Pharmacol 2006, 535:1-12.
9. Ishikawa Y., Sorota S., Kiuchi K., Shannon R.P., Komamura K., Katsushika S., Vatner D.E., Vatner S.F., Homcy C.J. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 1994, 93:2224-2229.
10. Okumura S., Kawabe J., Yatani A., Takagi G., Lee M.C., Hong C., Liu J., Takagi I., Sadoshima J., Vatner D.E., Vatner S.F., Ishikawa Y. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 2003, 93:364-371.
11. Okumura S., Takagi G., Kawabe J., Yang G., Lee M.C., Hong C., Liu J., Vatner D.E., Sadoshima J., Vatner S.F., Ishikawa Y. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 2003, 100:9986-9990.
12. Tang T., Lai N.C., Roth D.M., Drumm J., Guo T., Lee K.W., Han P.L., Dalton N., Gao M.H. Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to beta-adrenergic stimulation. Basic Res Cardiol 2006, 101:117-126.
13. Okumura S., Vatner D.E., Kurotani R., Bai Y., Gao S., Yuan Z., Iwatsubo K., Ulucan C., Kawabe J., Ghosh K., Vatner S.F., Ishikawa Y. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 2007, 116:1776-1783.
14. Vatner S.F., Yan L., Ishikawa Y., Vatner D.E., Sadoshima J. Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress. Circ J 2009, 73:195-200.
15. Hu C.L., Chandra R., Ge H., Pain J., Yan L., Babu G., Depre C., Iwatsubo K., Ishikawa Y., Sadoshima J., Vatner S.F., Vatner D.E. Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am J Physiol Heart Circ Physiol 2009, 297:H1776-H1782.
16. Tesmer J.J., Sunahara R.K., Gilman A.G., Sprang S.R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha. GTPgammaS Sci 1997, 278:1907-1916.
17. Whisnant R.E., Gilman A.G., Dessauer C.W. Interaction of the two cytosolic domains of mammalian adenylyl cyclase. Proc Natl Acad Sci USA 1996, 93:6621-6625.
18. Sunahara R.K., Dessauer C.W., Whisnant R.E., Kleuss C., Gilman A.G. Interaction of Gsalpha with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 1997, 272:22265-22271.
19. Dessauer C.W., Scully T.T., Gilman A.G. Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 1997, 272:22272-22277.
20. Tesmer J.J., Sunahara R.K., Johnson R.A., Gosselin G., Gilman A.G., Sprang S.R. Two-metal-Ion catalysis in adenylyl cyclase. Science 1999, 285:756-760.
21. Chen-Goodspeed M., Lukan A.N., Dessauer C.W. Modeling of Galpha(s) and Galpha(i) regulation of human type V and VI adenylyl cyclase. J Biol Chem 2005, 280:1808-1816.
22. Sadana R., Dessauer C.W. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 2009, 17:5-22.
23. Kapiloff M.S., Piggott L.A., Sadana R., Li J., Heredia L.A., Henson E., Efendiev R., Dessauer C.W. An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes. J Biol Chem 2009, 284:23540-23546.
24. Dessauer C.W. Adenylyl cyclase-A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 2009, 76:935-941.
25. Cooper D.M., Mons N., Karpen J.W. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 1995, 374:421-424.
26. Mons N., Decorte L., Jaffard R., Cooper D.M. Ca2+-sensitive adenylyl cyclases, key integrators of cellular signalling. Life Sci 1998, 62:1647-1652.
27. Cooper D.M. Regulation and organization of adenylyl cyclases and cAMP. Biochem J 2003, 375:517-529.
28. Cooper D.M. Compartmentalization of adenylate cyclase and cAMP signalling. Biochem Soc Trans 2005, 33:1319-1322.
29. Willoughby D., Cooper D.M. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 2007, 87:965-1010.
30. Choi E.J., Xia Z., Villacres E.C., Storm D.R. The regulatory diversity of the mammalian adenylyl cyclases. Curr Opin Cell Biol 1993, 5:269-273.
31. Xia Z., Storm D.R. Calmodulin-regulated adenylyl cyclases and neuromodulation. Curr Opin Neurobiol 1997, 7:391-396.
32. Ferguson G.D., Storm D.R. Why calcium-stimulated adenylyl cyclases?. Physiol (Bethesda) 2004, 19:271-276.
33. Tang W.J., Gilman A.G. Adenylyl cyclases. Cell 1992, 70:869-872.
34. Sunahara R.K., Dessauer C.W., Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 1996, 36:461-480.
35. Hanoune J., Pouille Y., Tzavara E., Shen T., Lipskaya L., Miyamoto N., Suzuki Y., Defer N. Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. Mol Cell Endocrinol 1997, 128:179-194.
36. Tesmer J.J., Sprang S.R. The structure, catalytic mechanism and regulation of adenylyl cyclase. Curr Opin Struct Biol 1998, 8:713-719.
37. Smit M.J., Iyengar R. Mammalian adenylyl cyclases. Adv Second Messenger Phosphoprotein Res 1998, 32:1-21.
38. Hurley J.H. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem 1999, 274:7599-7602.
39. Whisnant R.E., Gilman A.G., Dessauer C.W. Interaction of the two cytosolic domains of mammalian adenylyl cyclase. Proc Natl Acad Sci USA 1996, 93:6621-6625.
40. Chen-Goodspeed M., Lukan A.N., Dessauer C.W. Modeling of Galpha(s) and Galpha(i) regulation of human type V and VI adenylyl cyclase. J Biol Chem 2005, 280:1808-1816.
41. Wu G.C., Lai H.L., Lin Y.W., Chu Y.T., Chern Y. N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase. J Biol Chem 2001, 276:35450-35457.
42. Iwami G., Kawabe J., Ebina T., Cannon P.J., Homcy C.J., Ishikawa Y. Regulation of adenylyl cyclase by protein kinase A. J Biol Chem 1995, 270:12481-12484.
43. Lin T.H., Lai H.L., Kao Y.Y., Sun C.N., Hwang M.J., Chern Y. Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the regulatory N domain and two catalytic C1 and C2 domains. J Biol Chem 2002, 277:15721-15728.
44. Tang W.J., Gilman A.G. Construction of a soluble adenylyl cyclase activated by Gs alpha and forskolin. Science 1995, 268:1769-1772.
45. Yan S.Z., Hahn D., Huang Z.H., Tang W.J. Two cytoplasmic domains of mammalian adenylyl cyclase form a Gs alpha- and forskolin-activated enzyme in vitro. J Biol Chem 1996, 271:10941-10945.
46. Sayner S.L., Alexeyev M., Dessauer C.W., Stevens T. Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ Res 2006, 98:675-681.
47. Tang W.J., Stanzel M., Gilman A.G. Truncation and alanine-scanning mutants of type I adenylyl cyclase. Biochemistry 1995, 34:14563-14572.
48. Yan S.Z., Huang Z.H., Shaw R.S., Tang W.J. The conserved asparagine and arginine are essential for catalysis of mammalian adenylyl cyclase. J Biol Chem 1997, 272:12342-12349.
49. Ping P., Anzai T., Gao M., Hammond H.K. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol Heart Circ Physiol 1997, 273:H707-H717.
50. Roth D.M., Bayat H., Drumm J.D., Gao M.H., Swaney J.S., Ander A., Hammond H.K. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 2002, 105:1989-1994.
51. Takahashi T., Tang T., Lai N.C., Roth D.M., Rebolledo B., Saito M., Lew W.Y., Clopton P., Hammond H.K. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 2006, 114:388-396.
52. Timofeyev V., He Y., Tuteja D., Zhang Q., Roth D.M., Hammond H.K., Chiamvimonvat N. Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy. J Mol Cell Cardiol 2006, 41:170-181.
53. Sastry A., Arnold E., Gurji H., Iwasa A., Hassankhani A., Lai N.C., Roth D.M., Patel H.H., Hammond H.K., Narayan S.M. Adenylylcyclase VI overexpression facilitates atrioventricular nodal conduction in mice. J Am Coll Cardiol 2006, 48:559-565.
54. Roth D.M., Gao M.H., Lai N.C., Drumm J., Dalton N., Zhou J.Y., Zhu J., Entrikin D., Hammond H.K. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999, 99:3099-3102.
55. Lai N.C., Roth D.M., Gao M.H., Tang T., Dalton D., Lai Y.Y., Spellman M., Clopton P., Hammond H.K. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in CHF. Circulation 2004, 110:330-336.
56. Tang T., Gao M.H., Roth D.M., Guo T., Hammond H.K. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum Ca2+ uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol 2004, 287:H1906-H1912.
57. Lai N.C., Tang T., Gao M.H., Saito M., Takahashi T., Roth D.M., Hammond H.K. Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol 2008, 51:1490-1497.
58. Gao M., Ping P., Post S., Insel P.A., Tang R., Hammond H.K. Increased expression of adenylylcyclase type VI proportionately increases ß-adrenergic receptor-stimulated cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1998, 95:1038-1043.
59. Gao M., Lai N.C., Roth D.M., Zhou J., Anzai T., Dalton N., Hammond H.K. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 1999, 99:1618-1622.
60. Geng Y.J., Ishikawa Y., Vatner D.E., Wagner T.E., Bishop S.P., Vatner S.F., Homcy C.J. Apoptosis of cardiac myocytes in Gsα transgenic mice. Circ Res 1999, 84:34-42.
61. Engelhardt S., Hein L., Wiesmann F., Lohse M.J. Progressive hypertrophy and heart failure in ß1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999, 96:7059-7064.
62. Liggett S.B., Tepe N.M., Lorenz J.N., Canning A.M., Jantz T.D., Mitarai S., Yatani A., Dorn G.W. Early and delayed consequences of ß2-adrenergic receptor overexpression in mouse hearts, Critical role for expression level. Circulation 2000, 101:1707-1714.
63. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., Dorn G.W. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997, 94:121-126.
64. Lai N.C., Roth D.M., Gao M.H., Fine S., Head B.P., Zhu J., McKirnan M.D., Kwong C., Dalton N., Urasawa K., Roth D.A., Hammond H.K. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 2000, 102:2396-2401.
65. Quyyumi A.A., Dakak N., Mulcahy D., Andrews N.P., Husain S., Panza J.A., Cannon R.O. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol 1997, 29:308-317.
66. Hillegass W.B., Dean N.A., Liao L., Rhinehart R.G., Myers P.R. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Amer Coll Cardiol 2001, 37:1335-1343.
67. Resnic F.S., Wainstein M., Lee M.K., Behrendt D., Wainstein R.V., Ohno-Machado L., Kirshenbaum J.M., Rogers C.D., Popma J.J., Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003, 145:42-46.
68. Roth D.M., Lai N.C., Gao M.H., Fine S., McKirnan M.D., Roth D.A., Hammond H.K. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther 2004, 15:989-994.
69. Gao M.H., Bayat H., Zhou J.Y., Roth D.M., Drumm J.D., Burhan J., Hammond H.K. Controlled expression of cardiac-directed adenylylcyclase type IV provided increased contractile function. Cardiovasc Res 2002, 56:197-204.
70. Gao M.H., Tang T., Guo S.Q., Sun J.R., Feramisco J.F., Hammond H.K. Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3. J Biol Chem 2004, 279:38797-38802.
71. Gao M.H., Tang T., Guo T., Pestonjamasp K., Feramisco J.R., Hammond H.K. Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. J Biol Chem 2008, 283:33527-33535.
72. Gao M.H., Miyanohara A., Feramisco J.R., Tang T. Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochem Biophys Res Commun 2009, 384:193-198.
73. Yamamoto S., Kawamura K., James T.N. Intracellular distribution of adenylate cyclase in human cardiocytes determined by electron microscopic cytochemistry. Microsc Res Tech 1998, 40:479-487.
74. Drescher M.J., Kern R.C., Hatfield J.S., Drescher D.G. Cytochemical localization of adenylyl cyclase activity within the sensory epithelium of the trout saccule. Neurosci Lett 1995, 196:145-148.
75. Ostrom R.S., Liu X., Head B.P., Gregorian C., Seasholtz T.M., Insel P.A. Localization of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin domains. Mol Pharmacol 2002, 62:983-992.
76. Head B.P., Patel B.P., Roth D.M., Lai N.C., Niesman I.R., Farquhar M.G., Insel P.A. G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem 2005, 280:31036-31044.
77. Insel P.A., Head B.P., Patel H.H., Roth D.M., Bundey R.A., Swaney J.S. Caveolae and lipid rafts: G protein-coupled receptor signaling microdomains in cardiac myocytes. Biochem Soc Trans 2005, 33:1131-1134.
78. Palade G. Fine structure of blood capillaries. J Appl Physics 1953; 24: 1424, (Abstract).
79. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1955, 1:445-448.
80. Pike L.J. Lipid rafts: bringing order to chaos. J Lipid Res 2003, 44:655-667.
81. Gao M.H., Tang T., Miyanohara A., Feramisco J.R., Hammond H.K. Beta1βadrenergic receptor vs adenylyl cyclase 6 expression in cardiac myocytes: differences in transgene localization and intracellular signaling. Cell Signal 2010, 22:584-589.
82. Thangavel M., Liu X., Sun S.Q., Kaminsky J., Ostrom R.S. The C1 and C2 domains target human type 6 adenylyl cyclase to lipid rafts and caveolae. Cell Signal 2009, 21:301-308.
83. Gao M.H., Tang T., Miyanohara A., Guo A., Tang R., Roth D.M., Firth A.L., Yuan J.X., Hammond H.K. Cyclic AMP-dependent and cAMP-independent effects of adenylyl cyclase 6: Insights from a catalytically inactive mutant. Mol Pharmacol 2011, 79:381-388.
84. Sinnarajah S., Dessauer C.W., Srikumar D., Chen J., Yuen J., Yilma S., Dennis J.C., Morrison E.E., Vodyanoy V., Kehrl J.H. RGS2 regulates signal transduction in olfactory neurons by attenuating activation of adenylyl cyclase III. Nature 2001, 409:1051-1055.
85. Salim S., Sinnarajah S., Kehrl J.H., Dessauer C.W. Identification of RGS2 and type V adenylyl cyclase interaction sites. J Biol Chem 2003, 278:15842-15849.
86. Roy A.A., Baragli A., Bernstein L.S., Hepler J.R., Hébert T.E., Chidiac P. RGS2 interacts with Gs and adenylyl cyclase in living cells. Cell Signal 2006, 18:336-348.
87. Scholich K., Pierre S., Patel T.B. Protein associated with Myc (PAM) is a potent inhibitor of adenylyl cyclases. J Biol Chem 2001, 276:47583-47589.
88. Gao X., Patel T.B. Histidine residues 912 and 913 in protein associated with Myc are necessary for the inhibition of adenylyl cyclase activity. Mol Pharmacol 2005, 67:42-49.
89. Piggott L.A., Bauman A.L., Scott J.D., Dessauer C.W. The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain. Proc Natl Acad Sci USA 2008, 105:13835-13840.
90. Wang S.C., Lai H.L., Chiu Y.T., Ou R., Huang C.L., Chern Y. Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor. Biochem J 2007, 406:383-388.
91. Chou J.L., Huang C.L., Lai H.L., Hung A.C., Chien C.L., Kao Y.Y., Chern Y. Regulation of type VI adenylyl cyclase by Snapin, a SNAP25-binding protein. J Biol Chem 2004, 279:46271-46279.
92. Wang S.C., Lin J.T., Chern Y. Novel regulation of adenylyl cyclases by direct protein-protein interactions: insights from snapin and ric8a. Neurosignals 2009, 17:169-180.
93. Tang T., Gao M.H., Lai N.C., Firth A.L., Takahashi T., Guo T., Yuan J.X., Roth D.M., Hammond H.K. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired Ca2+ handling. Circulation 2008, 117:61-69.
94. Tepe N.M., Liggett S.B. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of beta-adrenergic receptor dysfunction in the G alph$alpha;q overexpressing mouse. FEBS Lett 1999, 458:236-240.
95. Esposito G., Perrino C., Ozaki T., Takaoka H., Defer N., Petretta M.P., De Angelis M.C., Mao L., Hanoune J., Rockman H.A., Chiariello M. Increased myocardial contractility and enhanced exercise function in transgenic mice overexpressing either adenylyl cyclase 5 or 8. Basic Res Cardiol 2008, 103:22-30.
96. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., Borow K., Dittrich H., Zsebo K.M., Hajjar R.J. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
97. Pleger S.T., Most P., Boucher M., Soltys S., Chuprun J.K., Pleger W., Gao E., Dasgupta A., Rengo G., Remppis A., Katus H.A., Eckhart A.D., Rabinowitz J.E., Koch W.J. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007, 115:2506-2515.
98. Vinge L.E., Raake P.W., Koch W.J. Gene therapy in heart failure. Circ Res 2008, 102:1458-1470.
99. Roth D.M., Lai N.C., Gao M.H., Drumm J.D., Jimenez J., Feramisco J.R., Hammond H.K. Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice. Am J Physiol 2004, 287:H172-H177.
100. Rebolledo B., Lai N.C., Gao M.H., Takahashi T., Roth D.M., Baird S.M., Hammond H.K. Adenylylcyclase gene transfer increases function of the failing heart. Hum Gene Ther 2006, 17:1043-1048.